vTv Therapeutics (VTVT) to Release Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

vTv Therapeutics Price Performance

Shares of VTVT stock traded up $1.95 on Friday, hitting $22.46. 4,279 shares of the stock traded hands, compared to its average volume of 23,282. vTv Therapeutics has a 52 week low of $12.12 and a 52 week high of $29.01. The firm has a 50 day simple moving average of $18.24 and a two-hundred day simple moving average of $16.44. The firm has a market cap of $71.65 million, a price-to-earnings ratio of -4.96 and a beta of 0.77.

Wall Street Analyst Weigh In

A number of research firms have commented on VTVT. HC Wainwright began coverage on vTv Therapeutics in a report on Wednesday, April 9th. They set a "buy" rating and a $36.00 price target on the stock. StockNews.com initiated coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They set a "sell" rating on the stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.